IMATINIB MESYLATE 400MG

Imatinib Mesylate 400 mg Tablet is a prescription targeted anticancer therapy classified as a tyrosine kinase inhibitor (TKI). It is widely prescribed for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and certain other malignancies, offering precision-targeted cancer care.

Imatinib works by blocking specific tyrosine kinase proteins that drive uncontrolled cancer cell growth. This targeted action helps slow disease progression, inhibit tumor growth, and improve long-term outcomes for patients with sensitive malignancies.

Taken under strict medical supervision, Imatinib Mesylate 400 mg Tablets provide clinically proven, long-term management of CML, GIST, and related cancers. Its oral tablet formulation ensures convenient daily administration while delivering effective, targeted anticancer therapy.

Product Features

• Tyrosine kinase inhibitor (TKI) therapy
• Imatinib is used in CML and GIST treatment
• Targets abnormal cancer cell signaling pathways
• Oral tablet for convenient administration
• Suitable for long-term therapy as prescribed
• Prescription-only oncology medication

How It Helps

• Blocks abnormal tyrosine kinase proteins to prevent uncontrolled cancer cell growth
• Slows disease progression in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)
• Helps control tumor growth while preserving healthy cells
• Supports long-term targeted therapy for improved patient outcomes